汇丰研究发表报告指,翰森制药(03692.HK) 在强劲的产品销售和业务拓展(BD)带动下,去年下半年业绩略微超出该行预期。该行预期公司长期销售可持续录得双位数增长,并推出创新产品及提升产能。维持“买入”评级,目标价由22元上调至24.2元。(ha/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-27 12:25。)AASTOCKS新闻
Source Link汇丰研究发表报告指,翰森制药(03692.HK) 在强劲的产品销售和业务拓展(BD)带动下,去年下半年业绩略微超出该行预期。该行预期公司长期销售可持续录得双位数增长,并推出创新产品及提升产能。维持“买入”评级,目标价由22元上调至24.2元。(ha/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-27 12:25。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.